Handok-Teva acquires commercialization approval for Symbicort generic

Published: 2016-03-21 14:09:51

Updated: 2016-03-31 13:29:58

A competitor against an AstraZeneca’s asthma and COPD drug recording annual KRW 10 billion sales, ‘Symbicort Turbuhaler(budesonide/formoterol),’ emerged.

As Handok-Teve succeeded in getting approval for its first generic, AstraZeneca happened to encounter competition in the Symbicort’s market soon.

According to the Ministry of Food and Drug Safety on the 17^th, Handok-Teva’s ‘DuoResp Spiroma...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.